Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer
ContributorsVafeiadou, Vasiliki ; Hany, Dina ; Picard, Didier
Published inCancers, vol. 14, no. 4, 954
Publication date2022-02-14
First online date2022-02-14
Abstract
Keywords
- ERα
- SPRED2
- Breast cancer
- Endocrine resistance
- Precision medicine
- Tamoxifen
- Ulixertinib
Research group
Citation (ISO format)
VAFEIADOU, Vasiliki, HANY, Dina, PICARD, Didier. Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer. In: Cancers, 2022, vol. 14, n° 4, p. 954. doi: 10.3390/cancers14040954
Main files (1)
Article (Published version)
Identifiers
- PID : unige:159290
- DOI : 10.3390/cancers14040954
- PMID : 35205702
- PMCID : PMC8870665
Commercial URLhttps://www.mdpi.com/2072-6694/14/4/954
ISSN of the journal2072-6694